Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
WuXi XDC Cayman Inc (2268.HK)
Wuxi, CN
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.98% | -3.00% | -6.79% | -13.06% | -16.12% | -9.63% | +37.42% | +96.07% | +96.07% | +96.07% | +96.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 18 | -2 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+46.7% ★ Q4'25: +186.9% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+34.9% ★ Q4'25: +486.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+22.6% ★ Q4'25: +19.4% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+27.3% ★ Q4'25: +26.3% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+33.4% ★ Q4'25: +69.7% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+2.9% Q4'25: +18.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.50× ★ Q4'25: 0.24× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 11 EPS Ana. |
Dec 2027 18 Rev. Ana. 12 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 11 Rev. Ana. 10 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
2.12B
est: 2.02B (+5.0%)
|
4.05B
est: 3.92B (+3.4%)
|
5.94B
est: 6.59B (-9.8%)
|
9.40B
9.26B – 9.86B
+42.7% YoY
|
12.51B
11.11B – 13.69B
+33.0% YoY
|
16.25B
15.11B – 17.47B
+30.0% YoY
|
19.65B
18.27B – 21.12B
+20.9% YoY
|
| EBITDA |
420.28M
est: 405.70M (+3.6%)
|
1.33B
est: 1.63B (-18.0%)
|
1.77B
est: 2.73B (-35.3%)
|
3.90B
3.84B – 4.09B
+42.7% YoY
|
5.19B
4.61B – 5.68B
+33.0% YoY
|
6.74B
6.27B – 7.24B
+30.0% YoY
|
8.15B
7.58B – 8.76B
+20.9% YoY
|
| EBIT |
365.50M
est: 293.53M (+24.5%)
|
1.22B
est: 1.63B (-24.9%)
|
1.62B
est: 2.74B (-40.8%)
|
3.91B
3.85B – 4.10B
+42.7% YoY
|
5.20B
4.62B – 5.69B
+33.0% YoY
|
6.75B
6.28B – 7.26B
+30.0% YoY
|
8.16B
7.59B – 8.78B
+20.9% YoY
|
| Net Income |
283.54M
est: 312.63M (-9.3%)
|
1.07B
est: 1.08B (-1.0%)
|
1.48B
est: 1.80B (-17.9%)
|
2.48B
2.28B – 2.60B
+37.9% YoY
|
3.41B
3.00B – 4.18B
+37.1% YoY
|
4.48B
4.07B – 4.91B
+31.4% YoY
|
5.30B
4.82B – 5.82B
+18.5% YoY
|
| SGA |
139.19M
est: 153.46M (-9.3%)
|
220.32M
est: 259.39M (-15.1%)
|
334.57M
est: 435.82M (-23.2%)
|
621.87M
612.30M – 652.04M
+42.7% YoY
|
827.33M
735.08M – 905.63M
+33.0% YoY
|
1.08B
999.89M – 1.16B
+30.0% YoY
|
1.30B
1.21B – 1.40B
+20.9% YoY
|
| EPS |
0.26
est: 0.24 (+7.1%)
|
0.89
est: 0.81 (+9.3%)
|
1.22
est: 1.36 (-10.3%)
|
1.87
1.72 – 1.96
+37.9% YoY
|
2.57
2.26 – 3.15
+37.1% YoY
|
3.38
3.07 – 3.71
+31.4% YoY
|
4.00
3.64 – 4.39
+18.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jincai Li | Chief Executive Officer & Executive Director | 5M | male |
| Xiaojie Xi | Company Secretary, Chief Financial Officer & Executive Director | 5M | male |
| Jingwei Zhang | Chief Operating Officer & Executive Director | 3M | male |
| Jianjun Luo | Vice President | — | — |
| Meiying Zhu | Chief Technology Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2268.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
